Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

Price charts only tell part of the story. Our team at StockStory evaluates each company's underlying fundamentals to separate temporary setbacks from structural declines. That said, here are two stocks where the poor sentiment is creating a buying opportunity and one facing legitimate challenges.

One-Month Return: -16.8%

Named after the three Cs of its original focus—carbon, cloud computing, and customer relationship management—C3.ai (NYSE:AI) provides enterprise AI software that helps organizations develop, deploy, and operate large-scale artificial intelligence applications across various industries.

Why Should You Sell AI?

Offerings struggled to generate meaningful interest as its average billings growth of 3.8% over the last year did not impress

Bad unit economics and steep infrastructure costs are reflected in its gross margin of 51.8%, one of the worst among software companies

Cash-burning history makes us doubt the long-term viability of its business model

At $11.67 per share, C3.ai trades at 4.5x forward price-to-sales. If you’re considering AI for your portfolio, see our FREE research report to learn more.

One-Month Return: -36.5%

With over 80% of U.S. physicians as members of its digital community, Doximity (NYSE:DOCS) operates a digital platform that enables physicians and other healthcare professionals to collaborate, stay current with medical news, manage their careers, and conduct virtual patient visits.

Why Are We Positive On DOCS?

Winning new contracts that can potentially increase in value as its billings growth has averaged 17.1% over the last year

Fast payback periods on sales and marketing expenses allow the company to invest heavily and onboard many customers concurrently

Strong free cash flow margin of 48.2% enables it to reinvest or return capital consistently

Doximity is trading at $27.81 per share, or 9.8x forward price-to-sales. Is now the time to initiate a position? See for yourself in our comprehensive research report, it’s free.

One-Month Return: +2.4%

Founded in 1965 and named after its original focus on "replacement lens insurance" for contact lens wearers, RLI (NYSE:RLI) is a specialty insurance company that underwrites property, casualty, and surety products through wholesale brokers, independent agents, and carrier partnerships.

Why Is RLI Interesting?

Market share has increased this cycle as its 13.7% annual revenue growth over the last five years was exceptional

Net premiums earned expanded by 13.3% annually over the last five years, demonstrating exceptional market penetration this cycle

Industry-leading 27.9% return on equity demonstrates management’s skill in finding high-return investments

RLI’s stock price of $61.58 implies a valuation ratio of 3.1x forward P/B. Is now a good time to buy? Find out in our full research report, it’s free.

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.